: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Migraine

Free Subscription

Articles published in Headache
Retrieve available abstracts of 384 articles:
HTML format

Single Articles

April 2024

GELFAND AA
Depression and anxiety are not associated with migraine outcomes in children and adolescents.
Headache. 2024 Apr 18. doi: 10.1111/head.14700.
PubMed

ROBBLEE J, Hakim SM, Reynolds JM, Monteith TS, et al
Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
Headache. 2024 Apr 18. doi: 10.1111/head.14693.
PubMed Abstract available

REINA-VARONA A, Madronero-Miguel B, Fierro-Marrero J, Paris-Alemany A, et al
Efficacy of various exercise interventions for migraine treatment: A systematic review and network meta-analysis.
Headache. 2024 Apr 10. doi: 10.1111/head.14696.
PubMed Abstract available

RIZVI BA, Kuziek J, Cho LY, Ronksley PE, et al
Anxiety and depressive symptoms and migraine-related outcomes in children and adolescents.
Headache. 2024 Apr 6. doi: 10.1111/head.14701.
PubMed Abstract available

March 2024

DODICK DW, Reed ML, Lee L, Balkaran BL, et al
Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States.
Headache. 2024 Mar 24. doi: 10.1111/head.14684.
PubMed Abstract available

KRIKOVA I, Digre KB, Katz BJ, Seay MD, et al
Migraine, idiopathic intracranial hypertension, and calcitonin gene-related peptide antibodies.
Headache. 2024 Mar 13. doi: 10.1111/head.14686.
PubMed

CHARLES AC, Digre KB, Goadsby PJ, Robbins MS, et al
Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Headache. 2024 Mar 11. doi: 10.1111/head.14692.
PubMed Abstract available

SPROUSE BLUM AS, DaSilva LA, Greenberg MD, Nissenbaum AJ, et al
Comparison of migraine with left- versus right-sided headache: A cross-sectional study.
Headache. 2024 Mar 3. doi: 10.1111/head.14689.
PubMed Abstract available

HOOGEVEEN ES, Pelzer N, Ghariq E, van Osch MJP, et al
Cerebrovascular reactivity to hypercapnia in patients with migraine: A dual-echo arterial spin labeling MRI study.
Headache. 2024 Mar 2. doi: 10.1111/head.14680.
PubMed Abstract available

GIBLER RC, Knestrick KE, Powers SW, Hershey AD, et al
Preliminary prospective observational investigation of clinical outcomes among treatment-seeking youth with continuous headache.
Headache. 2024;64:319-322.
PubMed

LIPTON RB, Albrecht D, Bermudez M, Hu J, et al
A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
Headache. 2024;64:266-275.
PubMed Abstract available

February 2024

SCUTELNIC A, Sutter NL, Beyeler M, Meinel TR, et al
Characteristics of acute ischemic stroke and unusual aura in patients with migraine with aura.
Headache. 2024 Feb 27. doi: 10.1111/head.14682.
PubMed Abstract available

CHHABRA N, Mead-Harvey C, Dodoo CA, Iser C, et al
Blood pressure elevation in erenumab-treated patients with migraine: A retrospective real-world experience.
Headache. 2024 Feb 27. doi: 10.1111/head.14679.
PubMed Abstract available

Correction to: "Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial".
Headache. 2024 Feb 26. doi: 10.1111/head.14691.
PubMed

ROSSIGNOL J, Ouimet T, Poras H, Dallel R, et al
Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine.
Headache. 2024 Feb 22. doi: 10.1111/head.14681.
PubMed Abstract available

MITTLEMAN MR, Mostofsky E, Vgontzas A, Bertisch SM, et al
Habitual caffeinated beverage consumption and headaches among adults with episodic migraine: A prospective cohort study.
Headache. 2024 Feb 6. doi: 10.1111/head.14673.
PubMed Abstract available

VAN DEN HOEK TC, Verhagen IE, de Boer I, Terwindt GM, et al
Substance use in a Dutch migraine cohort compared with the general population.
Headache. 2024 Feb 1. doi: 10.1111/head.14663.
PubMed Abstract available

LANGDON RL, DiSabella MT, Strelzik JA
Screen time and pediatric headache: A scoping review of the literature.
Headache. 2024;64:211-225.
PubMed Abstract available

HAN C, Lim JY, Koike N, Kim SY, et al
Regulation of headache response and transcriptomic network by the trigeminal ganglion clock.
Headache. 2024;64:195-210.
PubMed Abstract available

JICHA C, Pham K
Neuromodulation for primary headache disorders: Advantages and challenges.
Headache. 2024;64:226-228.
PubMed

PRADHAN SK, Gantenbein AR, Li Y, Shaban H, et al
Daith piercing: Revisited from the perspective of auricular acupuncture systems. A narrative review.
Headache. 2024;64:131-140.
PubMed Abstract available

January 2024

ZHANG P, Ventrapragada A, Shapiro RE, Do TP, et al
Metaphorical use of "headache" and "migraine" in media: A longitudinal study of 1.3 million articles in major publications.
Headache. 2024 Jan 18. doi: 10.1111/head.14661.
PubMed Abstract available

VGONTZAS A
Examining substance use patterns in adults with migraine: A changing landscape.
Headache. 2024 Jan 18. doi: 10.1111/head.14660.
PubMed

MANGRUM R, Bryant AL, Gerstein MT, McCarrier KP, et al
The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine.
Headache. 2024 Jan 18. doi: 10.1111/head.14664.
PubMed Abstract available

PATNIYOT I, Banerjee A, Nobleza K, Nguyen D, et al
A retrospective analysis of the use of candesartan for migraine prevention in adolescents.
Headache. 2024;64:96-97.
PubMed

DE OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
Persistent headache attributed to past ischemic stroke: A prospective cohort study.
Headache. 2024;64:48-54.
PubMed Abstract available

December 2023

BELTRAMONE M, Redon S, Donnet A
Bone site fracture pain after subcutaneous sumatriptan injection: A report of two cases.
Headache. 2023 Dec 29. doi: 10.1111/head.14662.
PubMed

RHUDY C, Schadler A, Huffmyer M, Porter L, et al
Rural disparities in emergency department utilization for migraine care.
Headache. 2023 Dec 12. doi: 10.1111/head.14659.
PubMed Abstract available

CHASE BA, Semenov I, Rubin S, Meyers S, et al
Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Headache. 2023 Dec 10. doi: 10.1111/head.14655.
PubMed Abstract available

November 2023

PODRAZA K, Bangera N, Feliz A, Charles A, et al
Reduction in retinal microvascular perfusion during migraine attacks.
Headache. 2023 Nov 30. doi: 10.1111/head.14654.
PubMed Abstract available

MACGREGOR EA, Okonkwo R, Detke HC, Polavieja P, et al
Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2.
Headache. 2023 Nov 28. doi: 10.1111/head.14652.
PubMed Abstract available

ASHINA M, Mitsikostas DD, Ramirez Campos V, Barash S, et al
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Headache. 2023 Nov 13. doi: 10.1111/head.14651.
PubMed Abstract available

WU J, Yang P, Wu X, Yu X, et al
Association between secondhand smoke exposure and severe headaches or migraine in never-smoking adults.
Headache. 2023 Nov 8. doi: 10.1111/head.14640.
PubMed Abstract available

SZPERKA CL, Witzman S, Ostapenko S, Farrar JT, et al
Patient headache questionnaires can improve headache diagnosis and treatment in children.
Headache. 2023;63:1359-1371.
PubMed Abstract available

IACONANGELO CJ, Serrano D, Adams AM, Trugman JM, et al
Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials.
Headache. 2023;63:1412-1422.
PubMed Abstract available

HYERACI G, Paoletti O, Iannone LF, Gini R, et al
Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
Headache. 2023;63:1391-1402.
PubMed Abstract available

MERLI E, Rustici A, Gramegna LL, Di Donato M, et al
Vessel-wall MRI in primary headaches: The role of neurogenic inflammation.
Headache. 2023;63:1372-1379.
PubMed Abstract available

October 2023

MOSKATEL LS, Graber-Naidich A, He Z, Zhang N, et al
The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
Headache. 2023 Oct 26. doi: 10.1111/head.14642.
PubMed Abstract available

CHIANG CC
Hypermobility spectrum disorders and migraine in adolescents.
Headache. 2023 Oct 24. doi: 10.1111/head.14650.
PubMed

PORTT AE, Orchard C, Chen H, Ge E, et al
Migraine and air pollution: A systematic review.
Headache. 2023 Oct 5. doi: 10.1111/head.14632.
PubMed Abstract available

LIPTON RB, Pozo-Rosich P, Orr SL, Reed ML, et al
Impact of monthly headache days on migraine-related quality of life: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study.
Headache. 2023 Oct 5. doi: 10.1111/head.14629.
PubMed Abstract available

MCCRACKEN HT, Lee AA, Smitherman TA
Headache and psychological variables as predictors of disability in individuals with primary headache disorders.
Headache. 2023;63:1259-1270.
PubMed Abstract available

September 2023

MD ISA NA, Tummanapalli SS, Chiang JCB, Krishnan AV, et al
Neuropathic changes in corneal nerve endings-A potential objective biomarker for migraine frequency and response to treatment.
Headache. 2023 Sep 23. doi: 10.1111/head.14630.
PubMed

WANG VS, Kosman J, Yuan H, Lauritsen C, et al
Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study.
Headache. 2023 Sep 23. doi: 10.1111/head.14636.
PubMed Abstract available

KRUSE JA, Seng EK
Changes in cognitive appraisal in a randomized controlled trial of mindfulness-based cognitive therapy for patients with migraine.
Headache. 2023 Sep 18. doi: 10.1111/head.14627.
PubMed Abstract available

SHAPIRO HFJ, Loder E, Shapiro DJ
Association between clinician specialty and prescription of preventive medication for young adults with migraine: A retrospective cohort study.
Headache. 2023 Sep 11. doi: 10.1111/head.14628.
PubMed Abstract available

SILVA-NETO RP, Soares AA, Souza WPO, Krymchantowski AG, et al
"Growing pains" in children and adolescents as an early symptom of migraine: A prospective study.
Headache. 2023 Sep 6. doi: 10.1111/head.14608.
PubMed Abstract available

CHARLES A
Aura is a symptom of a migraine attack, not its cause.
Headache. 2023 Sep 4. doi: 10.1111/head.14623.
PubMed

CLEMENTI MA, Kienzler C, Yonker M, Harmon M, et al
Preliminary exploration of a multidimensional sleep health composite in adolescent females with frequent migraine.
Headache. 2023 Sep 1. doi: 10.1111/head.14626.
PubMed Abstract available

LIU H, Zhang S, Gong Z, Zhao W, et al
Association between migraine and cardiovascular disease mortality: A prospective population-based cohort study.
Headache. 2023 Sep 1. doi: 10.1111/head.14616.
PubMed Abstract available

LEI X, Wei M, Wang L, Liu C, et al
Resting-state electroencephalography microstate dynamics altered in patients with migraine with and without aura-A pilot study.
Headache. 2023 Sep 1. doi: 10.1111/head.14622.
PubMed Abstract available

TEPPER SJ, Schwedt TJ, Vo P, Thompson J, et al
Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non-interventional study using claims data from the United States.
Headache. 2023 Sep 1. doi: 10.1111/head.14612.
PubMed Abstract available

MACGREGOR EA, Hutchinson S, Lai H, Dabruzzo B, et al
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
Headache. 2023 Sep 1. doi: 10.1111/head.14619.
PubMed Abstract available

Correction to "Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labelling".
Headache. 2023;63:1199.
PubMed

MARTINDALE C, Presson AP, Schwedt TJ, Brennan KC, et al
Sensory hypersensitivities are associated with post-traumatic headache-related disability.
Headache. 2023;63:1061-1069.
PubMed Abstract available

FILA M, Pawlowska E, Szczepanska J, Blasiak J, et al
Autophagy may protect the brain against prolonged consequences of headache attacks: A narrative/hypothesis review.
Headache. 2023;63:1154-1166.
PubMed Abstract available

KATSUKI M, Matsumori Y, Kawamura S, Kashiwagi K, et al
Developing an artificial intelligence-based diagnostic model of headaches from a dataset of clinic patients' records.
Headache. 2023;63:1097-1108.
PubMed Abstract available

August 2023

ZAMIR O, Yarns BC, Lagman-Bartolome AM, Jobanputra L, et al
Understanding the gaps in headache and migraine treatment with psychological and behavioral interventions: A narrative review.
Headache. 2023 Aug 28. doi: 10.1111/head.14624.
PubMed Abstract available

POLK AN, Smitherman TA
A meta-analytic review of acceptance-based interventions for migraine.
Headache. 2023 Aug 27. doi: 10.1111/head.14614.
PubMed Abstract available

RICHER L, Luu H, Martins KJB, Vu K, et al
Trajectory of health care resources among adults stopping or reducing treatment frequency of botulinum toxin for chronic migraine treatment in Alberta, Canada.
Headache. 2023 Aug 23. doi: 10.1111/head.14613.
PubMed Abstract available

MATSUMORI Y, Ishida M, Iba K, Kim BK, et al
Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials.
Headache. 2023 Aug 21. doi: 10.1111/head.14606.
PubMed Abstract available

KILINC YB, Kilinc E, Danis A, Hanci F, et al
Mitochondrial metabolism related markers GDF-15, FGF-21, and HIF-1alpha are elevated in pediatric migraine attacks.
Headache. 2023 Aug 19. doi: 10.1111/head.14618.
PubMed Abstract available

ORNELLO R, Bruno F, Frattale I, Curcio G, et al
White matter hyperintensities in migraine are not mediated by a dysfunction of the glymphatic system-A diffusion tensor imaging magnetic resonance imaging study.
Headache. 2023 Aug 18. doi: 10.1111/head.14607.
PubMed Abstract available

QIN Z, Qu H, Liang HB, Zhou Q, et al
Altered resting-state effective connectivity of trigeminal vascular system in migraine without aura: A spectral dynamic causal modeling study.
Headache. 2023 Aug 7. doi: 10.1111/head.14602.
PubMed Abstract available

YANG L, Zhou Y, Zhang L, Wang Y, et al
Aryl hydrocarbon receptors improve migraine-like pain behaviors in rats through the regulation of regulatory T cell/T-helper 17 cell-related homeostasis.
Headache. 2023 Aug 4. doi: 10.1111/head.14599.
PubMed Abstract available

July 2023

NAHMAN-AVERBUCH H, Callahan D, Darken R, Haroutounian S, et al
Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment-A narrative review.
Headache. 2023 Jul 31. doi: 10.1111/head.14601.
PubMed Abstract available

GELFAND AA, Allen IE, Grimes B, Irwin S, et al
Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.
Headache. 2023 Jul 19. doi: 10.1111/head.14600.
PubMed Abstract available

MEHNERT J, Fischer-Schulte L, May A
Aura phenomena do not initiate migraine attacks-Findings from neuroimaging.
Headache. 2023 Jul 14. doi: 10.1111/head.14597.
PubMed Abstract available

DE VRIES LENTSCH S, Perenboom MJL, Carpay JA, MaassenVanDenBrink A, et al
Visual hypersensitivity in patients treated with anti-calcitonin gene-related peptide (receptor) monoclonal antibodies.
Headache. 2023;63:926-933.
PubMed Abstract available

REIDY BL, Riddle EJ, Powers SW, Slater SK, et al
Biopsychosocial treatment response among youth with continuous headache: A retrospective, clinic-based study.
Headache. 2023;63:942-952.
PubMed Abstract available

June 2023

LANE IA, Zempsky WT
Capturing the experiences of sexual and gender minorities with migraine headache.
Headache. 2023 Jun 27. doi: 10.1111/head.14595.
PubMed

JICHA CJ, Alex A, Herskovitz S, Haut SR, et al
Migraine with prolonged aphasic aura associated with a CACNA1A mutation: A case report and narrative review.
Headache. 2023 Jun 27. doi: 10.1111/head.14594.
PubMed Abstract available

NAGRI A, Patel M, Mwansisya T, Adebayo PB, et al
Development and initial validation of the Kiswahili version of the Migraine Disability Assessment (MIDAS-K) questionnaire.
Headache. 2023 Jun 27. doi: 10.1111/head.14592.
PubMed Abstract available

DANNO D, Ishizaki K, Kikui S, Takeshima T, et al
Treatment of hemiplegic migraine with anti-calcitonin gene-related peptide monoclonal antibodies: A case series in a tertiary-care headache center.
Headache. 2023 Jun 27. doi: 10.1111/head.14591.
PubMed Abstract available

BOCZARSKA-JEDYNAK M, Blumenfeld AM
Injection technique of the upper face with onabotulinumtoxinA in chronic migraine.
Headache. 2023 Jun 27. doi: 10.1111/head.14588.
PubMed Abstract available

PERETZ A, Stark-Inbar A, Harris D, Tamir S, et al
Safety of remote electrical neuromodulation for acute migraine treatment in pregnant women: A retrospective controlled survey-study.
Headache. 2023 Jun 19. doi: 10.1111/head.14586.
PubMed

RODRIGUEZ-RIVAS R, Moreno-Martinez CA, Cerqueira TL, Enriquez-Peregrino KG, et al
Translation, cross-cultural adaptation, and validation of a Latin American Spanish version of the ID Migraine screening test.
Headache. 2023 Jun 16. doi: 10.1111/head.14509.
PubMed Abstract available

MANGANO GD, Capizzi MR, Mantuano E, Veneziano L, et al
Familial hemiplegic migraine in pediatric patients: A genetic, clinical, and follow-up study.
Headache. 2023 Jun 16. doi: 10.1111/head.14582.
PubMed Abstract available

COHEN F, Bobker S
From diet to disasters, lifestyle factors can affect headaches and migraine.
Headache. 2023 Jun 15. doi: 10.1111/head.14500.
PubMed

AHMED Z, Honomichl R, Thompson SF, Cohen JM, et al
Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
Headache. 2023 Jun 14. doi: 10.1111/head.14527.
PubMed Abstract available

YU B, Hou S, Xing Y, Jia Z, et al
Ultrasound-guided stellate ganglion block for the treatment of migraine in elderly patients: A retrospective and observational study.
Headache. 2023 Jun 14. doi: 10.1111/head.14537.
PubMed Abstract available

TEPPER SJ, Lipton RB, Silberstein SD, Kudrow D, et al
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Headache. 2023 Jun 14. doi: 10.1111/head.14536.
PubMed Abstract available

SENG EK, Parker A, Shapiro RE, Buse DC, et al
Living in society, living with migraine: Editorial for the 2022 Members' Choice Award paper.
Headache. 2023 Jun 14. doi: 10.1111/head.14530.
PubMed

ZLOOF Y, Simchoni M, Derazne E, Tsur AM, et al
Hypermobility spectrum disorders and active migraine in Israeli adolescents: A nationwide study.
Headache. 2023 Jun 14. doi: 10.1111/head.14526.
PubMed Abstract available

ZHANG Y, Smith JH, Mullan AF, Vanmeter DE, et al
Frequency of headache in emergency department patients with anaphylaxis: A cross-sectional study.
Headache. 2023;63:834-838.
PubMed Abstract available

KARSAN N, Bose RP, O'Daly O, Zelaya F, et al
Regional cerebral perfusion during the premonitory phase of triggered migraine: A double-blind randomized placebo-controlled functional imaging study using pseudo-continuous arterial spin labeling.
Headache. 2023;63:771-787.
PubMed Abstract available

PARK SY, Kim J
Characteristics of patients who visited emergency departments for headache in South Korea: A descriptive cross-sectional study.
Headache. 2023;63:795-804.
PubMed Abstract available

May 2023

SACCA F, Braca S, Sansone M, Miele A, et al
A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Headache. 2023 May 31. doi: 10.1111/head.14528.
PubMed Abstract available

LAU CI, Chen WH, Wang HC, Walsh V, et al
Decision-making impairment under ambiguity but not under risk may underlie medication overuse in patients with chronic migraine.
Headache. 2023 May 26. doi: 10.1111/head.14513.
PubMed Abstract available

HANS A, Stonnington CM, Zhang N, Butterfield R, et al
The impact of resilience on headache disability as measured by the Migraine Disability Assessment (MIDAS).
Headache. 2023 May 23. doi: 10.1111/head.14518.
PubMed Abstract available

LIPTON RB, Sico J, Seng EK
Migraine screening in English and Spanish.
Headache. 2023 May 4. doi: 10.1111/head.14520.
PubMed

MANGRUM R, Gerstein MT, Hall CJ 3rd, Buse DC, et al
Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine.
Headache. 2023 May 4. doi: 10.1111/head.14521.
PubMed Abstract available

KELLIER DJ, de Prado BM, Haagen D, Grabner P, et al
Validity of self-reported migraine in adolescents and children.
Headache. 2023 May 4. doi: 10.1111/head.14498.
PubMed Abstract available

TEPPER SJ, Dong Y, Vincent M, Wietecha LA, et al
Sustained response of galcanezumab in migraine prevention: Patient-level data from a post hoc analysis in patients with episodic or chronic migraine.
Headache. 2023 May 3. doi: 10.1111/head.14494.
PubMed Abstract available

MEI HR, Hu YY, Kapadia S, Ouimet T, et al
Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors.
Headache. 2023;63:621-633.
PubMed Abstract available

ACKLEY E, Asamoah P, Mirsky D, White C, et al
Dots and spots: A retrospective review of T2-hyperintense white matter lesions in pediatric patients with and without headache.
Headache. 2023;63:611-620.
PubMed Abstract available

HOULE TT, Smith MR, Turner DP
Common challenges in the development of prediction models.
Headache. 2023;63:569-570.
PubMed

KATSUKI M, Tatsumoto M, Kimoto K, Iiyama T, et al
Investigating the effects of weather on headache occurrence using a smartphone application and artificial intelligence: A retrospective observational cross-sectional study.
Headache. 2023;63:585-600.
PubMed Abstract available

April 2023

WANG Z, Lin Q, Peng YB
Multi-region local field potential signatures and brain coherence alternations in response to nitroglycerin-induced migraine attacks.
Headache. 2023 Apr 10. doi: 10.1111/head.14506.
PubMed Abstract available

CHEN YJ, Hu KF, Chan C, Huang C, et al
Association of periodontal disease with migraine: A large-scale community-based cross-sectional study.
Headache. 2023 Apr 10. doi: 10.1111/head.14491.
PubMed Abstract available

CARMILLO L, Fasano A
Fremanezumab plus plasmapheresis in a patient with chronic migraine and myasthenia gravis: Case report of an effective treatment.
Headache. 2023 Apr 10. doi: 10.1111/head.14497.
PubMed Abstract available

THOMPSON AC, Goodbourn PT, Forte JD
Perceived severity of Visual Snow Syndrome is associated with visual allodynia.
Headache. 2023;63:494-505.
PubMed Abstract available

March 2023

OLIVEIRA FAA, Dourado-Filho MG, Sampaio Rocha-Filho PA
Assessing the influence of migraine on ischemic penumbra and on the prognosis of ischemic stroke: A prospective cohort study.
Headache. 2023 Mar 29. doi: 10.1111/head.14492.
PubMed Abstract available

DIGRE KB
Good New? Bad News? Idiopathic intracranial hypertension and migraine.
Headache. 2023 Mar 29. doi: 10.1111/head.14489.
PubMed

GRAF M, Kim E, Brewer I, Hernandez J, et al
Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel.
Headache. 2023 Mar 15. doi: 10.1111/head.14479.
PubMed Abstract available

GERSTEIN MT, Wirth RJ, Uzumcu AA, Houts CR, et al
Patient-reported experiences with migraine-related cognitive symptoms: Results of the MiCOAS qualitative study.
Headache. 2023 Mar 10. doi: 10.1111/head.14484.
PubMed Abstract available

VERHAGEN IE, van der Arend BWH, van Casteren DS, le Cessie S, et al
Sex differences in migraine attack characteristics: A longitudinal E-diary study.
Headache. 2023;63:333-341.
PubMed Abstract available

KUDROW D, Dafer R, Dodick DW, Starling A, et al
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long-term clinical trial data.
Headache. 2023;63:418-428.
PubMed Abstract available

BASEDAU H, Oppermann T, Gundelwein Silva E, Peng KP, et al
Characterization of trigeminal C-fiber reactivity through capsaicin-induced release of calcitonin gene-related peptide.
Headache. 2023;63:353-359.
PubMed Abstract available

ACKLEY E, Gibler RC, Orr SL, Powers SW, et al
Virtual issue: Recent advances in pediatric headache: Bridging the data gap.
Headache. 2023;63:305-306.
PubMed

February 2023

ESTAVE PM, Margol C, Beeghly S, Anderson R, et al
Mechanisms of mindfulness in patients with migraine: Results of a qualitative study.
Headache. 2023 Feb 28. doi: 10.1111/head.14481.
PubMed Abstract available

LIPTON RB, Buse DC, Sandoe CH, Ford JH, et al
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.
Headache. 2023 Feb 16. doi: 10.1111/head.14460.
PubMed Abstract available

GIBLER RC, Peugh JL, Coffey CS, Chamberlin LA, et al
Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments.
Headache. 2023 Feb 9. doi: 10.1111/head.14474.
PubMed Abstract available

BSTEH G, Macher S, Krajnc N, Pruckner P, et al
Idiopathic intracranial hypertension presenting with migraine phenotype is associated with unfavorable headache outcomes.
Headache. 2023 Feb 8. doi: 10.1111/head.14478.
PubMed Abstract available

SCHWEDT TJ, Martin A, Kymes S, Talon B, et al
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
Headache. 2023 Feb 8. doi: 10.1111/head.14476.
PubMed Abstract available

BUTLER N, Snyder IC, Korn TG, Nicholson RA, et al
Lifetime history of an anxiety or depression disorder and adherence to medications used for the acute treatment of migraine.
Headache. 2023 Feb 8. doi: 10.1111/head.14477.
PubMed Abstract available

BATUR P, Yao M, Bucklan J, Soni P, et al
Use of combined hormonal contraception and stroke: A case-control study of the impact of migraine type and estrogen dose on ischemic stroke risk.
Headache. 2023 Feb 8. doi: 10.1111/head.14473.
PubMed Abstract available

AL-KARAGHOLI MA, Kalatharan V, Ghanizada H, Dussor G, et al
Prolactin in headache and migraine: A systematic review of preclinical studies.
Headache. 2023 Feb 8. doi: 10.1111/head.14412.
PubMed Abstract available

EZZATI A, Fanning KM, Reed ML, Lipton RB, et al
Predictors of treatment-response to caffeine combination products, acetaminophen, acetylsalicylic acid (aspirin), and nonsteroidal anti-inflammatory drugs in acute treatment of episodic migraine.
Headache. 2023 Feb 7. doi: 10.1111/head.14459.
PubMed Abstract available

MOLLAN SP, Subramanian A, Perrins M, Nirantharakumar K, et al
Depression and anxiety in women with idiopathic intracranial hypertension compared to migraine: A matched controlled cohort study.
Headache. 2023 Feb 7. doi: 10.1111/head.14465.
PubMed Abstract available

ZOLIN A, Broner SW, Yoo A, Guan I, et al
Dystonia phenomenology and treatment response in migraine.
Headache. 2023;63:255-263.
PubMed Abstract available

MCGINLEY JS, Savord A, Buse DC, Wirth RJ, et al
Longitudinal assessment of comorbidities and co-occurring conditions in adolescents with migraine: A secondary analysis of the National Longitudinal Study of Adolescent to Adult Health (Add Health).
Headache. 2023;63:243-254.
PubMed Abstract available

COCORES AN, Goadsby PJ, Monteith TS
Post-vaccination headache reporting: Trends according to the Vaccine Adverse Events Reporting System.
Headache. 2023;63:275-282.
PubMed Abstract available

DODICK DW, Blumenfeld AM, Halker Singh RB, Williams R, et al
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
Headache. 2023;63:233-242.
PubMed Abstract available

January 2023

BASARI A, Boran HE, Vuralli D, Cengiz B, et al
Visual temporal discrimination is impaired in patients with migraine without aura.
Headache. 2023 Jan 27. doi: 10.1111/head.14466.
PubMed Abstract available

WELANDER NZ, Rukh G, Rask-Andersen M, Harder AVE, et al
Migraine, inflammatory bowel disease and celiac disease: A Mendelian randomization study.
Headache. 2023 Jan 27. doi: 10.1111/head.14470.
PubMed Abstract available

TEPPER SJ, Rabany L, Cowan RP, Smith TR, et al
Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial.
Headache. 2023 Jan 27. doi: 10.1111/head.14469.
PubMed Abstract available

VERHAAK A, Bakaysa S, Johnson A, Veronesi M, et al
Migraine treatment in pregnancy: A survey of comfort and treatment practices of women's healthcare providers.
Headache. 2023 Jan 25. doi: 10.1111/head.14436.
PubMed Abstract available

ZHANG X, Wang W, Bai X, Zhang Y, et al
Changes in gamma-aminobutyric acid and glutamate/glutamine levels in the right thalamus of patients with episodic and chronic migraine: A proton magnetic resonance spectroscopy study.
Headache. 2023 Jan 18. doi: 10.1111/head.14449.
PubMed Abstract available

ASHINA M, Tepper SJ, Reuter U, Blumenfeld AM, et al
Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Headache. 2023 Jan 18. doi: 10.1111/head.14439.
PubMed Abstract available

CASANOVA A, Vives-Mestres M, Donoghue S, Mian A, et al
The role of avoiding known triggers, embracing protectors, and adhering to healthy lifestyle recommendations in migraine prophylaxis: Insights from a prospective cohort of 1125 people with episodic migraine.
Headache. 2023 Jan 18. doi: 10.1111/head.14451.
PubMed Abstract available

STARLING AJ, Cowan RP, Buse DC, Diener HC, et al
Eptinezumab improved patient-reported outcomes in patients with migraine and medication-overuse headache: Subgroup analysis of the randomized PROMISE-2 trial.
Headache. 2023 Jan 12. doi: 10.1111/head.14434.
PubMed Abstract available

BAHTIRI L, Thomsen AV, Ashina M, Hougaard A, et al
Migraine aura-like episodes following sclerotherapy for varicose veins of the lower extremities-A systematic review.
Headache. 2023 Jan 12. doi: 10.1111/head.14448.
PubMed Abstract available

BLUMENFELD AM, Boinpally R, De Abreu Ferreira R, Trugman JM, et al
Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Headache. 2023 Jan 5. doi: 10.1111/head.14433.
PubMed Abstract available

URTECHO M, Wagner B, Wang Z, VanderPluym JH, et al
A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes.
Headache. 2023 Jan 5. doi: 10.1111/head.14430.
PubMed Abstract available

LIU H, Wang Q, Dong Z, Yu S, et al
Dietary zinc intake and migraine in adults: a cross-sectional analysis of the National Health and Nutrition Examination Survey 1999-2004.
Headache. 2023 Jan 1. doi: 10.1111/head.14431.
PubMed Abstract available

STERN JI, Datta S, Chiang CC, Garza I, et al
Narrative review of migraine management in patients with renal or hepatic disease.
Headache. 2023;63:9-24.
PubMed Abstract available

SCUTELNIC A, Slavova N, Klein A, Horvath T, et al
Symptomatic visual snow in acute ischemic stroke: A case series.
Headache. 2023;63:173-176.
PubMed Abstract available

DONG Z, Liu K, Liu H, Jia Z, et al
The prevalence and clinical features of fibromyalgia in Chinese hospital patients with primary headache: The survey of fibromyalgia comorbid with headache.
Headache. 2023;63:62-70.
PubMed Abstract available

ZORRILLA N, Gelfand AA, Irwin SL
Eptinezumab for adolescents with chronic refractory headache: A retrospective chart review.
Headache. 2023;63:177-182.
PubMed Abstract available

BEGASSE DE DHAEM O, Wattiez AS, de Boer I, Pavitt S, et al
Bridging the gap between preclinical scientists, clinical researchers, and clinicians: From animal research to clinical practice.
Headache. 2023;63:25-39.
PubMed Abstract available

November 2022

KALTSEIS K, Hamann T, Gaul C, Broessner G, et al
Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review.
Headache. 2022 Nov 27. doi: 10.1111/head.14415.
PubMed Abstract available

VIVES-MESTRES M, Casanova A, Puig X, Ginebra J, et al
Alcohol as a trigger of migraine attacks in people with migraine. Results from a large prospective cohort study in English-speaking countries.
Headache. 2022 Nov 27. doi: 10.1111/head.14428.
PubMed Abstract available

SOUZA MNP, Cohen JM, Piha T, Ribalov R, et al
Burden of migraine in Brazil: A cross-sectional real-world study.
Headache. 2022 Nov 25. doi: 10.1111/head.14413.
PubMed Abstract available

THAXTER LY, Smitherman TA
The effect of the COVID-19 pandemic on headache-related disability among young adults with migraine.
Headache. 2022 Nov 23. doi: 10.1111/head.14411.
PubMed Abstract available

GUI T, Li H, Zhu F, Wang Q, et al
Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.
Headache. 2022 Nov 14. doi: 10.1111/head.14423.
PubMed Abstract available

HENNINGSEN P, Hausteiner-Wiehle C, Hauser W
Migraine in the context of chronic primary pain, chronic overlapping pain disorders, and functional somatic disorders: A narrative review.
Headache. 2022 Nov 14. doi: 10.1111/head.14419.
PubMed Abstract available

GARCIA-AZORIN D
The complex relationship between alcohol and migraine.
Headache. 2022 Nov 14. doi: 10.1111/head.14426.
PubMed

SENG EK, Shapiro RE, Buse DC, Robbins MS, et al
The unique role of stigma in migraine-related disability and quality of life.
Headache. 2022 Nov 2. doi: 10.1111/head.14401.
PubMed Abstract available

BEDRIN K, Ailani J, Dougherty C
Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
Headache. 2022;62:1419-1423.
PubMed Abstract available

DHOOT R, Sengupta S
Recurrent painful ophthalmoplegic neuropathy with headache and oculomotor palsy 18 years apart.
Headache. 2022;62:1434-1436.
PubMed

CARLSEN LN, Bendtsen L, Jensen RH, Schytz HW, et al
Telephone follow-up on treatment and patient satisfaction at a Danish tertiary headache center: A prospective study.
Headache. 2022;62:1312-1321.
PubMed Abstract available

MEMBRILLA JA, Torres-Ferrus M, Alpuente A, Caronna E, et al
Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
Headache. 2022;62:1395-1405.
PubMed Abstract available

October 2022

CROOP R, Madonia J, Stock DA, Thiry A, et al
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Headache. 2022 Oct 14. doi: 10.1111/head.14389.
PubMed Abstract available

GARELJA ML, Hay DL
A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene-related peptide and beyond.
Headache. 2022 Oct 13. doi: 10.1111/head.14388.
PubMed Abstract available

FOFI L, Altamura C, Fiorentini G, Brunelli N, et al
Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.
Headache. 2022 Oct 7. doi: 10.1111/head.14400.
PubMed Abstract available

HARPE J, Bernstein C, Harriott A
Migraine and infertility, merging concepts in women's reproductive health: A narrative review.
Headache. 2022 Oct 6. doi: 10.1111/head.14402.
PubMed Abstract available

YONKER ME, McVige J, Zeitlin L, Visser H, et al
A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.
Headache. 2022;62:1207-1217.
PubMed Abstract available

STERN JI, Chiang CC, Kissoon NR, Robertson CE, et al
Narrative review of peripheral nerve blocks for the management of headache.
Headache. 2022;62:1077-1092.
PubMed Abstract available

FISCHER-SCHULTE L, May A
The 15-day threshold in the definition of chronic migraine is reasonable and sufficient-Five reasons for not changing the ICHD-3 definition.
Headache. 2022;62:1231-1233.
PubMed

BELTRAMONE M, Redon S, Fernandes S, Ducros A, et al
The teaching of headache medicine in France: A questionnaire-based study.
Headache. 2022;62:1177-1186.
PubMed Abstract available

ORR SL, Shapiro RE
The elephant in the room: How the underfunding of headache research stunts the field.
Headache. 2022;62:1234-1238.
PubMed

September 2022

BURCH R
A non-oral gepant for acute treatment of migraine.
Headache. 2022 Sep 16. doi: 10.1111/head.14397.
PubMed

KUDROW D, Nguyen L, Semler J, Stroud C, et al
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.
Headache. 2022 Sep 16. doi: 10.1111/head.14390.
PubMed Abstract available

LI D, Guo Y, Xia M, Zhang J, et al
Dietary intake of thiamine and riboflavin in relation to severe headache or migraine: A cross-sectional survey.
Headache. 2022 Sep 1. doi: 10.1111/head.14384.
PubMed Abstract available

HUBIG LT, Smith T, Chua GN, Lloyd AJ, et al
A stated preference survey to explore patient preferences for novel preventive migraine treatments.
Headache. 2022 Sep 1. doi: 10.1111/head.14386.
PubMed Abstract available

August 2022

LOPEZ-BRAVO A, Oliveros-Cid A, Minguez-Olaondo A, Cuadrado ML, et al
Nummular headache responsive to anti-calcitonin gene-related peptide monoclonal antibodies in a patient with migraine.
Headache. 2022 Aug 26. doi: 10.1111/head.14372.
PubMed Abstract available

OLIVEIRA AB, Peres MFP, Mercante JPP, Molina MDCB, et al
Physical activity pattern and migraine according to aura symptoms in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort: A cross-sectional study.
Headache. 2022 Aug 26. doi: 10.1111/head.14380.
PubMed Abstract available

MONTERREY P, Gonzalez M, Ramirez D, Gracia F, et al
Characteristics of migraine in patients with headache disorders: A clinic-based study from Central American and Caribbean countries.
Headache. 2022 Aug 26. doi: 10.1111/head.14375.
PubMed Abstract available

July 2022

NAGARAJ K, Wei DY, Puledda F, Weng HY, et al
Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype.
Headache. 2022 Jul 21. doi: 10.1111/head.14362.
PubMed Abstract available

CHIANG CC, Schwedt TJ, Dodick DW
Exploring the association between migraine and atrial fibrillation utilizing a novel artificial intelligence-ECG algorithm.
Headache. 2022 Jul 21. doi: 10.1111/head.14366.
PubMed

MUELLER BR, Robinson-Papp J
Postural orthostatic tachycardia syndrome and migraine: A narrative review.
Headache. 2022 Jul 19. doi: 10.1111/head.14365.
PubMed Abstract available

LEE W, Cho SJ, Hwang H, Lee M, et al
Crystal-clear days and unclear days in migraine: A population-based study.
Headache. 2022 Jul 14. doi: 10.1111/head.14359.
PubMed Abstract available

BEMANALIZADEH M, Baghaei Oskouei H, Hadizadeh A, Dakkali MS, et al
Paroxysmal hemicrania in children and adolescents: A systematic review.
Headache. 2022 Jul 14. doi: 10.1111/head.14354.
PubMed Abstract available

MARTAMI F, Jayedi A, Shab-Bidar S
Primary headache disorders and body mass index categories: A systematic review and dose-response meta-analysis.
Headache. 2022;62:801-810.
PubMed Abstract available

MOSKATEL LS, Smirnoff L
Protracted headache after COVID-19: A case series of 31 patients from a tertiary headache center.
Headache. 2022;62:903-907.
PubMed Abstract available

RADZIWON J, Waszak P
Seasonal changes of internet searching suggest circannual rhythmicity of primary headache disorders.
Headache. 2022;62:811-817.
PubMed Abstract available

June 2022

TEPPER SJ, Grosberg B, Daniel O, Kuruvilla DE, et al
Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial.
Headache. 2022 Jun 24. doi: 10.1111/head.14350.
PubMed Abstract available

BERTELS Z, Mangutov E, Conway C, Siegersma K, et al
Migraine and peripheral pain models show differential alterations in neuronal complexity.
Headache. 2022 Jun 8. doi: 10.1111/head.14352.
PubMed Abstract available

CHIANG CC, Chhabra N, Chao CJ, Wang H, et al
Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men.
Headache. 2022 Jun 8. doi: 10.1111/head.14339.
PubMed Abstract available

PERO A, Pace A, Dhamoon MS
Triptan medication use among patients with migraine with contraindications in the US.
Headache. 2022 Jun 7. doi: 10.1111/head.14327.
PubMed Abstract available

CASANOVA A, Vives-Mestres M, Donoghue S, Mian A, et al
An observational study of self-reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App).
Headache. 2022 Jun 7. doi: 10.1111/head.14328.
PubMed Abstract available

RICHER LP, Ali S, Johnson DW, Rosychuk RJ, et al
A randomized trial of ketorolac and metoclopramide for migraine in the emergency department.
Headache. 2022 Jun 7. doi: 10.1111/head.14307.
PubMed Abstract available

BUOITE STELLA A, Filingeri D, Garascia G, D'Acunto L, et al
Skin wetness sensitivity across body sites commonly affected by pain in people with migraine.
Headache. 2022 Jun 7. doi: 10.1111/head.14323.
PubMed Abstract available

GELFAND AA, Halker Singh RB, Robbins MS
Worsening migraine: Another casualty of natural disasters.
Headache. 2022 Jun 7. doi: 10.1111/head.14325.
PubMed

COWAN RP, Rapoport AM, Blythe J, Rothrock J, et al
Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi-center study.
Headache. 2022 Jun 3. doi: 10.1111/head.14324.
PubMed Abstract available

SAMPAIO ROCHA-FILHO PA
Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management.
Headache. 2022;62:650-656.
PubMed Abstract available

May 2022

EZZATI A, Fanning KM, Buse DC, Pavlovic JM, et al
Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.
Headache. 2022 May 11. doi: 10.1111/head.14312.
PubMed Abstract available

LEE DA, Lee HJ, Park KM
Normal glymphatic system function in patients with migraine: A pilot study.
Headache. 2022 May 11. doi: 10.1111/head.14320.
PubMed Abstract available

SCHWEDT TJ, Robert T, Dodick DW
Treatment of chronic migraine with medication overuse: A perspective.
Headache. 2022 May 6. doi: 10.1111/head.14314.
PubMed

HSU TW, Chen MH, Chu CS, Tsai SJ, et al
Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study.
Headache. 2022 May 6. doi: 10.1111/head.14306.
PubMed Abstract available

KHAYATA MJ, Farley S, Davis JK, Hornik CP, et al
Beyond pain control: Outcome and treatment preferences in pediatric migraine.
Headache. 2022 May 6. doi: 10.1111/head.14315.
PubMed Abstract available

SCHIM JD, Anderson C, Brunner E, Hirman J, et al
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Headache. 2022 May 6. doi: 10.1111/head.14302.
PubMed Abstract available

CARVALHO GF, Luedtke K, Pinheiro CF, Moraes R, et al
Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors.
Headache. 2022;62:548-557.
PubMed Abstract available

ASHINA M, Tepper SJ, Brandes JL, Reuter U, et al
Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Headache. 2022;62:624-633.
PubMed Abstract available

LEIBOVIT-REIBEN Z, Ishii R, Dodick DW, Dumkrieger G, et al
The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research.
Headache. 2022;62:566-576.
PubMed Abstract available

ZEBENHOLZER K, Gall W, Gleiss A, Pavelic AR, et al
Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
Headache. 2022;62:604-612.
PubMed Abstract available

YOUSEF YENGEJ D, Nwaobi SE, Ferando I, Kechechyan G, et al
Different characteristics of cortical spreading depression in the sleep and wake states.
Headache. 2022;62:577-587.
PubMed Abstract available

April 2022

NAHMAN-AVERBUCH H, Schneider VJ 2nd, Lee GR, Peugh JL, et al
New insight into the neural mechanisms of migraine in adolescents: Relationships with sleep.
Headache. 2022 Apr 25. doi: 10.1111/head.14299.
PubMed Abstract available

TU YH, Wang YF, Yuan H, Chen SP, et al
Most bothersome symptoms in patients with migraine: A hospital-based study in Taiwan.
Headache. 2022 Apr 25. doi: 10.1111/head.14308.
PubMed Abstract available

VIG SJ, Garza J, Tao Y
The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
Headache. 2022 Apr 25. doi: 10.1111/head.14305.
PubMed Abstract available

OKAZAKI Y, Yoshida S, Kashima S, Koike S, et al
Impact of the 2018 Japan Floods on prescriptions for migraine: A longitudinal analysis using the National Database of Health Insurance Claims.
Headache. 2022 Apr 25. doi: 10.1111/head.14301.
PubMed Abstract available

LIPTON RB, Goadsby PJ, Dodick DW, McGinley JS, et al
Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
Headache. 2022 Apr 25. doi: 10.1111/head.14295.
PubMed Abstract available

BECKER WJ, Spacey S, Leroux E, Giammarco R, et al
A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Headache. 2022 Apr 10. doi: 10.1111/head.14291.
PubMed Abstract available

FERRARI MD, Zuurbier KWM, Barash S, Ning X, et al
Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
Headache. 2022 Apr 6. doi: 10.1111/head.14294.
PubMed

SILVESTRO M, Tessitore A, Orologio I, Battista G, et al
Cluster headache pathophysiology: What we have learned from advanced neuroimaging.
Headache. 2022;62:436-452.
PubMed Abstract available

March 2022

HARRIS L, L'Italien G, Kumar A, Seelam P, et al
Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.
Headache. 2022 Mar 28. doi: 10.1111/head.14289.
PubMed Abstract available

SENG EK, Lipton RB
Do behavioral treatments work for migraine prevention?
Headache. 2022 Mar 16. doi: 10.1111/head.14290.
PubMed

BUSE DC, Gerstein MT, Houts CR, McGinley JS, et al
Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study.
Headache. 2022 Mar 16. doi: 10.1111/head.14274.
PubMed Abstract available

CARVALHO GF, Becnel AR, Miske C, Szikszay TM, et al
Postural control impairment in patients with headaches-A systematic review and meta-analysis.
Headache. 2022;62:241-270.
PubMed Abstract available

February 2022

AILANI J, Winner P, Hartry A, Brevig T, et al
Patient preference for early onset of efficacy of preventive migraine treatments.
Headache. 2022 Feb 20. doi: 10.1111/head.14255.
PubMed Abstract available

GRECO R, Demartini C, Zanaboni AM, Francavilla M, et al
The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain.
Headache. 2022 Feb 18. doi: 10.1111/head.14267.
PubMed Abstract available

KLAN T, Brascher AK, Klein S, Diezemann-Prossdorf A, et al
Assessing attack-related fear in headache disorders-Structure and psychometric properties of the Fear of Attacks in Migraine Inventory.
Headache. 2022 Feb 18. doi: 10.1111/head.14272.
PubMed Abstract available

TIETJEN GE
The relationship of childhood adversity and migraine and the value of prospective studies.
Headache. 2022 Feb 9. doi: 10.1111/head.14268.
PubMed

TEPPER SJ, Sheikh HU, Dougherty CO, Nahas SJ, et al
Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
Headache. 2022 Feb 9. doi: 10.1111/head.14266.
PubMed Abstract available

KAWATA AK, Ladd MK, Lipton RB, Buse DC, et al
Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
Headache. 2022 Feb 8. doi: 10.1111/head.14258.
PubMed Abstract available

DUDENEY J, Sharpe L, McDonald S, Menzies RE, et al
Are psychological interventions efficacious for adults with migraine? A systematic review and meta-analysis.
Headache. 2022 Feb 5. doi: 10.1111/head.14260.
PubMed Abstract available

DI ANTONIO S, Castaldo M, Ponzano M, Bovis F, et al
Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine.
Headache. 2022 Feb 5. doi: 10.1111/head.14261.
PubMed Abstract available

GOLLION C, Guidolin B, Lerebours F, Rousseau V, et al
Migraine and large artery atherosclerosis in young adults with ischemic stroke.
Headache. 2022 Feb 5. doi: 10.1111/head.14265.
PubMed Abstract available

HAMMOND NG, Colman I, Orr SL
Adverse childhood experiences and onset of migraine in Canadian adolescents: A cohort study.
Headache. 2022 Feb 5. doi: 10.1111/head.14256.
PubMed Abstract available

GIL YE, Lee MJ, Cho S, Chung CS, et al
Effect of caffeine and caffeine cessation on cerebrovascular reactivity in patients with migraine.
Headache. 2022 Feb 3. doi: 10.1111/head.14263.
PubMed Abstract available

SHAO Q, Rascati KL, Barner JC, Lawson KA, et al
Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension-type headache enrolled in commercial insurance plans.
Headache. 2022;62:141-158.
PubMed Abstract available

AILANI J, Kuruppu DK, Rettiganti M, Oakes T, et al
Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
Headache. 2022;62:198-207.
PubMed Abstract available

January 2022

LIPTON RB, Nicholson RA, Reed ML, Araujo AB, et al
Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.
Headache. 2022 Jan 25. doi: 10.1111/head.14259.
PubMed Abstract available

ARTEMENKO AR, Filatova E, Vorobyeva YD, Do TP, et al
Migraine and light: A narrative review.
Headache. 2022;62:4-10.
PubMed Abstract available

ELSER H, Skajaa N, Ehrenstein V, Fuglsang CH, et al
Cancer risk in patients with migraine: A population-based cohort study in Denmark.
Headache. 2022;62:57-64.
PubMed Abstract available

December 2021

MASON BN, Kallianpur R, Price TJ, Akopian AN, et al
Prolactin signaling modulates stress-induced behavioral responses in a preclinical mouse model of migraine.
Headache. 2021 Dec 29. doi: 10.1111/head.14248.
PubMed Abstract available

LIPTON RB, Gandhi P, Stokes J, Cala ML, et al
Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
Headache. 2021 Dec 28. doi: 10.1111/head.14229.
PubMed Abstract available

AILANI J, Blumenfeld AM
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
Headache. 2021 Dec 7. doi: 10.1111/head.14244.
PubMed

BURCH RC, Ailani J, Robbins MS
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
Headache. 2021 Dec 7. doi: 10.1111/head.14245.
PubMed

OLIVEIRA ADP, Silva-Neto RP
Circadian rhythmicity on red ear syndrome in a patient with migraine: A case report.
Headache. 2021 Dec 7. doi: 10.1111/head.14242.
PubMed Abstract available

GONZALEZ-MARTINEZ A, Trillo Senin S, Benavides Bernaldo de Queiros C, Casado Fernandez L, et al
Clinical characteristics and perfusion-computed tomography alterations in a series of patients with migraine with aura attended as stroke code.
Headache. 2021 Dec 3. doi: 10.1111/head.14243.
PubMed Abstract available

November 2021

CHARLES JA, Turner IM
AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?
Headache. 2021 Nov 28. doi: 10.1111/head.14232.
PubMed

MCALLISTER PJ, Turner I, Reuter U, Wang A, et al
Timing and durability of response to erenumab in patients with episodic migraine.
Headache. 2021 Nov 28. doi: 10.1111/head.14233.
PubMed Abstract available

LEE JH, Shewale AR, Barthold D, Devine B, et al
Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Headache. 2021 Nov 28. doi: 10.1111/head.14238.
PubMed Abstract available

OZKAN E, Gursoy-Ozdemir Y
Occipital bending in migraine with visual aura.
Headache. 2021 Nov 28. doi: 10.1111/head.14240.
PubMed Abstract available

GLADSTONE J, Chhibber S, Minhas J, Neish CS, et al
Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
Headache. 2021 Nov 22. doi: 10.1111/head.14218.
PubMed Abstract available

KAZI F, Manyapu M, Fakherddine M, Mekuria K, et al
Second-line interventions for migraine in the emergency department: A narrative review.
Headache. 2021 Nov 22. doi: 10.1111/head.14239.
PubMed Abstract available

CHARLES A, Nwaobi SE, Goadsby P
Inflammation in migraine...or not...: A critical evaluation of the evidence.
Headache. 2021 Nov 22. doi: 10.1111/head.14224.
PubMed

VYAS MV, Saposnik G, Lay C
Migraine and sun avoidance behaviors in Canadian adults.
Headache. 2021 Nov 2. doi: 10.1111/head.14227.
PubMed

RAGAB AH, Kishk NA, Hassan A, Yacoub O, et al
Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study.
Headache. 2021 Nov 2. doi: 10.1111/head.14231.
PubMed Abstract available

HINDIYEH N
Can we anticipate how Ramadan fasting will affect migraine?
Headache. 2021;61:1463-1464.
PubMed

KELLY AM, Kuan WS, Chu KH, Kinnear FB, et al
Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)-A multinational observational study.
Headache. 2021;61:1539-1552.
PubMed Abstract available

October 2021

YUAN H, Curran JG, Keith SW, Hopkins MM, et al
Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study.
Headache. 2021 Oct 3. doi: 10.1111/head.14214.
PubMed Abstract available

GALLARDO VJ, Alpuente A, Cerda-Company X, Torres-Ferrus M, et al
The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish.
Headache. 2021 Oct 3. doi: 10.1111/head.14225.
PubMed Abstract available

PRICE A, Sumner P, Powell G
Subjective sensory sensitivity and its relationship with anxiety in people with probable migraine.
Headache. 2021;61:1342-1350.
PubMed Abstract available

NABITY PS, Jaramillo CA, Resick PA, McGeary CA, et al
Persistent posttraumatic headaches and functioning in veterans: Injury type can matter.
Headache. 2021;61:1334-1341.
PubMed Abstract available

STRAUSS LD, Yugrakh MS, Kaplan KE, Minen MT, et al
Headache infusion centers: A survey on treatments provided, infusion center operations, and barriers to developing new infusion centers.
Headache. 2021;61:1364-1375.
PubMed Abstract available

September 2021

DODICK DW, Tepper SJ, Ailani J, Pannacciulli N, et al
Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data.
Headache. 2021 Sep 30. doi: 10.1111/head.14208.
PubMed Abstract available

KLEIN A, Schankin CJ
Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review.
Headache. 2021 Sep 27. doi: 10.1111/head.14213.
PubMed Abstract available

MARMURA MJ, Diener HC, Cowan RP, Tepper SJ, et al
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
Headache. 2021 Sep 22. doi: 10.1111/head.14206.
PubMed Abstract available

CHARLES A
Memantine for migraine-Big promise but little evidence.
Headache. 2021;61:1151-1152.
PubMed

SENG EK
Stress and migraine: I know it when I see it.
Headache. 2021;61:1153-1155.
PubMed

YALINAY DIKMEN P, Ertas M, Kosak S, Cimentepe C, et al
Primary headaches among gender dysphoric female-to-male individuals: A cross-sectional survey on gender transition experience.
Headache. 2021;61:1194-1206.
PubMed Abstract available

HOULE TT, Deng H, Tegeler CH, Turner DP, et al
Continuous updating of individual headache forecasting models using Bayesian methods.
Headache. 2021;61:1264-1273.
PubMed Abstract available

BREEN ID, Mangold AR, VanderPluym JH
The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon.
Headache. 2021;61:1274-1276.
PubMed

FREITAG FG
Everything old is new again.
Headache. 2021;61:1286.
PubMed

August 2021

KIM SK, Nikolova S, Schwedt TJ
Structural aberrations of the brain associated with migraine: A narrative review.
Headache. 2021 Aug 18. doi: 10.1111/head.14189.
PubMed Abstract available

SPIERINGS ELH, Ning X, Ramirez Campos V, Cohen JM, et al
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b
Headache. 2021 Aug 10. doi: 10.1111/head.14196.
PubMed Abstract available

VIVES-MESTRES M, Casanova A, Hershey AD, Orr SL, et al
Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data.
Headache. 2021 Aug 9. doi: 10.1111/head.14199.
PubMed Abstract available

ZHANG N, Woldeamanuel YW
Medication overuse headache in patients with chronic migraine using cannabis: A case-referent study.
Headache. 2021 Aug 9. doi: 10.1111/head.14195.
PubMed Abstract available

TEPPER SJ, Lucas S, Ashina M, Schwedt TJ, et al
Timing and durability of response to erenumab in patients with chronic migraine.
Headache. 2021 Aug 7. doi: 10.1111/head.14193.
PubMed Abstract available

SMITH TR, Winner P, Aurora SK, Jeleva M, et al
STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD((R)) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
Headache. 2021 Aug 7. doi: 10.1111/head.14184.
PubMed Abstract available

CARONNA E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P, et al
Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios.
Headache. 2021 Aug 7. doi: 10.1111/head.14197.
PubMed Abstract available

COHEN F, Friedman BW
A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis.
Headache. 2021 Aug 7. doi: 10.1111/head.14185.
PubMed Abstract available

MISTRY VM, Morizio PL, Pepin MJ, Bryan WE, et al
Role of memantine in the prophylactic treatment of episodic migraine: A systematic review.
Headache. 2021 Aug 5. doi: 10.1111/head.14186.
PubMed Abstract available

July 2021

SAKAI F, Suzuki N, Kim BK, Igarashi H, et al
Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Headache. 2021 Jul 29. doi: 10.1111/head.14169.
PubMed Abstract available

SAKAI F, Suzuki N, Kim BK, Tatsuoka Y, et al
Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
Headache. 2021 Jul 29. doi: 10.1111/head.14178.
PubMed Abstract available

BARBANTI P, Aurilia C, Cevoli S, Egeo G, et al
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Headache. 2021 Jul 26. doi: 10.1111/head.14194.
PubMed Abstract available

ARCA KN, VanderPluym JH, Halker Singh RB
Narrative review of neuroimaging in migraine with aura.
Headache. 2021 Jul 26. doi: 10.1111/head.14191.
PubMed Abstract available

THOMSEN AV, Sorensen MT, Ashina M, Hougaard A, et al
Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity.
Headache. 2021 Jul 12. doi: 10.1111/head.14187.
PubMed Abstract available

SAMPAIO ROCHA-FILHO PA, Albanes Oliveira Bernardo A
The usefulness of osmophobia for the diagnosis of migraine in children and adolescents.
Headache. 2021 Jul 4. doi: 10.1111/head.14175.
PubMed

ISHII R
Should chronic migraine be defined by eight or more headache days per month?
Headache. 2021;61:983-984.
PubMed

WELLS RE, Estave PM, Burch R, Haas N, et al
The value of the patient perspective in understanding the full burden of migraine.
Headache. 2021;61:985-987.
PubMed

MINEN MT, Szperka CL, Kaplan K, Ehrlich A, et al
Telehealth as a new care delivery model: The headache provider experience.
Headache. 2021;61:1123-1131.
PubMed Abstract available

KUMAR G, Payne AM, Maag LM, MacDonald S, et al
Efficacy of a pediatric headache infusion center: A single-center experience.
Headache. 2021;61:1086-1091.
PubMed Abstract available

CARLSEN LN, Rouw C, Westergaard ML, Nielsen M, et al
Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial.
Headache. 2021;61:1112-1122.
PubMed Abstract available

June 2021

AILANI J, Burch RC, Robbins MS
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
Headache. 2021 Jun 23. doi: 10.1111/head.14153.
PubMed Abstract available

TAKESHIMA T, Sakai F, Hirata K, Imai N, et al
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Headache. 2021 Jun 21. doi: 10.1111/head.14138.
PubMed Abstract available

RIZZOLI PB, Grazzi L
Adaptation of the management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVID-19 pandemic: Lessons from a tertiary headache center in Milan-6-month results.
Headache. 2021 Jun 21. doi: 10.1111/head.14140.
PubMed

BHARADWAJ VN, Porreca F, Cowan RP, Kori S, et al
A new hypothesis linking oxytocin to menstrual migraine.
Headache. 2021 Jun 14. doi: 10.1111/head.14152.
PubMed Abstract available

BARBANTI P, Fofi L, Grazzi L, Vernieri F, et al
Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project.
Headache. 2021 Jun 14. doi: 10.1111/head.14123.
PubMed Abstract available

GRAZZI L, Andrasik F, Rizzoli P, Bernstein C, et al
Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation.
Headache. 2021 Jun 11. doi: 10.1111/head.14139.
PubMed Abstract available

ASHINA M, Cohen JM, Gandhi SK, Du E, et al
Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
Headache. 2021 Jun 11. doi: 10.1111/head.14127.
PubMed Abstract available

SILVA-NETO RP
Could osmophobia be a clinical diagnostic marker for migraine?
Headache. 2021 Jun 9. doi: 10.1111/head.14148.
PubMed

KIM BK, Cho S, Kim HY, Chu MK, et al
Validity and reliability of the self-administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic-based study.
Headache. 2021 Jun 9. doi: 10.1111/head.14133.
PubMed Abstract available

ISHII R, Schwedt TJ, Dumkrieger G, Lalvani N, et al
Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.
Headache. 2021 Jun 3. doi: 10.1111/head.14154.
PubMed Abstract available

ESTAVE PM, Beeghly S, Anderson R, Margol C, et al
Learning the full impact of migraine through patient voices: A qualitative study.
Headache. 2021 Jun 3. doi: 10.1111/head.14151.
PubMed Abstract available

SCHUSTER NM, Gasperi M
Not just preaching to the CHOIR-A map for improving comprehensive care of patients with chronic migraine and comorbid non-cephalic pain.
Headache. 2021;61:805-807.
PubMed

JOSHI S, Tepper SJ, Lucas S, Rasmussen S, et al
A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.
Headache. 2021;61:838-853.
PubMed Abstract available

LIANG Z, Thomas L, Jull G, Minto J, et al
Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction.
Headache. 2021;61:882-894.
PubMed Abstract available

NAHMAN-AVERBUCH H, Hershey AD, Peugh JL, King CD, et al
The promise of mechanistic approaches to understanding how youth with migraine get better-An Editorial to the 2020 Members' Choice Award Paper.
Headache. 2021;61:803-804.
PubMed

BARAD MJ, Sturgeon JA, Hong J, Aggarwal AK, et al
Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study.
Headache. 2021;61:872-881.
PubMed Abstract available

May 2021

POPOFF E, Johnston K, Croop R, Thiry A, et al
Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
Headache. 2021 May 22. doi: 10.1111/head.14128.
PubMed Abstract available

CHIANG CC, Halker Singh R, Lalvani N, Shubin Stein K, et al
Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.
Headache. 2021 May 21. doi: 10.1111/head.14110.
PubMed Abstract available

LIPTON RB, Dodick DW, Ailani J, McGill L, et al
Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
Headache. 2021 May 20. doi: 10.1111/head.14120.
PubMed Abstract available

SAKAI F, Takeshima T, Homma G, Tanji Y, et al
Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
Headache. 2021 May 15. doi: 10.1111/head.14122.
PubMed Abstract available

ZIPLOW J
The importance of studying comorbidities in migraine.
Headache. 2021;61:697.
PubMed

GREENE KA
The status of intravenous dihydroergotamine for pediatric headache: Status migrainosus and beyond.
Headache. 2021;61:698-699.
PubMed

April 2021

JAKATE A, Blumenfeld AM, Boinpally R, Butler M, et al
Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Headache. 2021 Apr 5. doi: 10.1111/head.14095.
PubMed Abstract available

YIN JH, Lin YK, Yang CP, Liang CS, et al
Prevalence and association of lifestyle and medical-, psychiatric-, and pain-related comorbidities in patients with migraine: A cross-sectional study.
Headache. 2021 Apr 5. doi: 10.1111/head.14106.
PubMed Abstract available

AURORA SK, Shrewsbury SB, Ray S, Hindiyeh N, et al
A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.
Headache. 2021 Apr 1. doi: 10.1111/head.14099.
PubMed Abstract available

BUSE DC, Armand CE, Charleston L 4th, Reed ML, et al
Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
Headache. 2021 Apr 1. doi: 10.1111/head.14103.
PubMed Abstract available

HODGSON SE, Harding AM, Bourke EM, Taylor DM, et al
A prospective, randomized, double-blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department.
Headache. 2021 Apr 1. doi: 10.1111/head.14091.
PubMed Abstract available

LIPTON RB, Cohen JM, Galic M, Seminerio MJ, et al
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
Headache. 2021;61:662-672.
PubMed Abstract available

MARMURA MJ
Comparing treatments in the emergency department: What works for migraine?
Headache. 2021;61:567-568.
PubMed

HINES DM, Shah S, Multani JK, Wade RL, et al
Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
Headache. 2021;61:590-602.
PubMed Abstract available

March 2021

NAEGEL S, Burow P, Holle D, Stoevesandt D, et al
Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.
Headache. 2021 Mar 29. doi: 10.1111/head.14101.
PubMed

TRIVEDI M, Dumkrieger G, Chong CD, Dodick DW, et al
Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research.
Headache. 2021 Mar 29. doi: 10.1111/head.14100.
PubMed Abstract available

SAKAI F, Takeshima T, Tatsuoka Y, Hirata K, et al
Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Headache. 2021 Mar 25. doi: 10.1111/head.14096.
PubMed Abstract available

LIU Y, Xu F, Wheaton AG, Greenlund KJ, et al
The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016.
Headache. 2021 Mar 23. doi: 10.1111/head.14087.
PubMed Abstract available

VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six-week prospective cohort study of patients with episodic migraine.
Headache. 2021 Mar 22. doi: 10.1111/head.14105.
PubMed Abstract available

WITTEN A, Marotta D, Cohen-Gadol A
Developmental innervation of cranial dura mater and migraine headache: A narrative literature review.
Headache. 2021 Mar 22. doi: 10.1111/head.14102.
PubMed Abstract available

COWAN RP, Gross NB, Sweeney MD, Sagare AP, et al
Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen.
Headache. 2021 Mar 16. doi: 10.1111/head.14088.
PubMed Abstract available

BLUMENFELD AM, Goadsby PJ, Dodick DW, Hutchinson S, et al
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
Headache. 2021;61:422-429.
PubMed Abstract available

February 2021

ASHINA H, Moskowitz MA
Shared biological foundations of post-traumatic headache and migraine.
Headache. 2021 Feb 25. doi: 10.1111/head.14084.
PubMed

MCGINLEY JS, Wirth RJ, Pavlovic JM, Donoghue S, et al
Between and within-woman differences in the association between menstruation and migraine days.
Headache. 2021 Feb 19. doi: 10.1111/head.14058.
PubMed Abstract available

MCGINLEY JS, Houts CR, Nishida TK, Buse DC, et al
Systematic review of outcomes and endpoints in preventive migraine clinical trials.
Headache. 2021 Feb 18. doi: 10.1111/head.14069.
PubMed Abstract available

SHAO Q, Rascati KL, Lawson KA, Wilson JP, et al
Impact of emergency department opioid use on future health resource utilization among patients with migraine.
Headache. 2021 Feb 18. doi: 10.1111/head.14071.
PubMed Abstract available

KAWATA AK, Shah N, Poon JL, Shaffer S, et al
Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Headache. 2021 Feb 16. doi: 10.1111/head.14053.
PubMed Abstract available

GELFAND AA, Ross AC, Pavitt S, Szperka CL, et al
Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency? A response.
Headache. 2021 Feb 5. doi: 10.1111/head.14061.
PubMed

GELFAND AA, Poland G
Migraine treatment and COVID-19 vaccines: no cause for concern.
Headache. 2021 Feb 5. doi: 10.1111/head.14086.
PubMed Abstract available

VANDERPLUYM JH
Once too many: Impact of emergency department opioid use on future health resource utilization among patients with migraine.
Headache. 2021;61:229-230.
PubMed

BURCH R
Outcomes in clinical trials for migraine: What should we measure and who should decide?
Headache. 2021;61:227-228.
PubMed

HOUTS CR, McGinley JS, Nishida TK, Buse DC, et al
Systematic review of outcomes and endpoints in acute migraine clinical trials.
Headache. 2021;61:263-275.
PubMed Abstract available

PINTO MJ, Guerrero AL, Costa A
Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia.
Headache. 2021;61:392-395.
PubMed Abstract available

January 2021

SLAVIN M, Li H, Khatri M, Frankenfeld C, et al
Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001-2004.
Headache. 2021 Jan 27. doi: 10.1111/head.14065.
PubMed Abstract available

SPECK RM, Yu R, Ford JH, Ayer DW, et al
Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
Headache. 2021 Jan 22. doi: 10.1111/head.14031.
PubMed Abstract available

NEIVA GR, Meira E Cruz M, Salles C
Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency?
Headache. 2021 Jan 20. doi: 10.1111/head.14060.
PubMed

SCHWEDT TJ, Hentz JG, Sahai-Srivastava S, Spare NM, et al
Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.
Headache. 2021 Jan 12. doi: 10.1111/head.14056.
PubMed Abstract available

PAVLOVIC JM, Yu JS, Silberstein SD, Reed ML, et al
Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group.
Headache. 2021 Jan 9. doi: 10.1111/head.14035.
PubMed Abstract available

LIAMPAS I, Mylonas KS, Brotis A, Dervenis P, et al
Serum lipid abnormalities in migraine: A meta-analysis of observational studies.
Headache. 2021 Jan 4. doi: 10.1111/head.14039.
PubMed Abstract available

O'BRIEN HL, Halker Singh RB
Breaking down barriers to care: Understanding migraine knowledge gaps among women's healthcare providers.
Headache. 2021;61:7-8.
PubMed

KARVOUNIDES D, Marzouk M, Ross AC, VanderPluym JH, et al
The intersection of COVID-19, school, and headaches: Problems and solutions.
Headache. 2021;61:190-201.
PubMed Abstract available

BERTELS Z, Witkowski WD, Asif S, Siegersma K, et al
A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia.
Headache. 2021;61:170-178.
PubMed Abstract available

December 2020

OSWALD JC, Schuster NM
A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment.
Headache. 2020 Dec 31. doi: 10.1111/head.14044.
PubMed

SPECTOR AR, Kerkow JF, Collins TA
Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report.
Headache. 2020 Dec 31. doi: 10.1111/head.14055.
PubMed

CONNELLY MA, Boorigie ME
Feasibility of using "SMARTER" methodology for monitoring precipitating conditions of pediatric migraine episodes.
Headache. 2020 Dec 31. doi: 10.1111/head.14028.
PubMed Abstract available

CHENG V, Billups SJ, Saseen JJ
Prescribing practices of migraine-specific pharmacotherapy associated with emergency department use for migraine.
Headache. 2020 Dec 30. doi: 10.1111/head.14029.
PubMed Abstract available

VERHAAK AMS, Williamson A, Johnson A, Murphy A, et al
Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers.
Headache. 2020 Dec 30. doi: 10.1111/head.14027.
PubMed Abstract available

PRESSMAN AR, Buse DC, Jacobson AS, Vaidya SJ, et al
The migraine signature study: Methods and baseline results.
Headache. 2020 Dec 23. doi: 10.1111/head.14033.
PubMed Abstract available

BURCH R, Rizzoli P, Loder E
The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys.
Headache. 2020 Dec 21. doi: 10.1111/head.14024.
PubMed Abstract available

HAGAN KK, Li W, Mostofsky E, Bertisch SM, et al
Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine.
Headache. 2020 Dec 21. doi: 10.1111/head.14037.
PubMed Abstract available

HERSHEY AD, Lin T, Gruper Y, Harris D, et al
Remote electrical neuromodulation for acute treatment of migraine in adolescents.
Headache. 2020 Dec 21. doi: 10.1111/head.14042.
PubMed Abstract available

BARBANTI P, Aurilia C, Egeo G, Fofi L, et al
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Headache. 2020 Dec 18. doi: 10.1111/head.14032.
PubMed Abstract available

TORABI SJ, Kasle DA, Savoca EL, Gottschalk CH, et al
Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population.
Headache. 2020 Dec 18. doi: 10.1111/head.14040.
PubMed Abstract available

LIPTON RB, Buse DC, Dodick DW, Schwedt TJ, et al
Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
Headache. 2020 Dec 16. doi: 10.1111/head.14018.
PubMed Abstract available

SMITH M, Nakamoto M, Crocker J, Tiffany Morden F, et al
Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey.
Headache. 2020 Dec 14. doi: 10.1111/head.14030.
PubMed Abstract available

DIENER HC, Marmura MJ, Tepper SJ, Cowan R, et al
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Headache. 2020 Dec 13. doi: 10.1111/head.14036.
PubMed Abstract available

November 2020

GELFAND AA, Pavitt S, Ross AC, Szperka CL, et al
Later high school start time is associated with lower migraine frequency in adolescents.
Headache. 2020 Nov 25. doi: 10.1111/head.14016.
PubMed Abstract available

NAHMAN-AVERBUCH H, Thomas PL, Schneider VJ 2nd, Chamberlin LA, et al
Spatial aspects of pain modulation are not disrupted in adolescents with migraine.
Headache. 2020 Nov 24. doi: 10.1111/head.14017.
PubMed Abstract available

TIRITICCO M, Vanotti A, Mantica D, Coppola A, et al
Migraine With Exclusive Olfactory Aura: Case Report and Literature Review.
Headache. 2020 Nov 18. doi: 10.1111/head.14014.
PubMed Abstract available

MINEN MT, Adhikari S, Padikkala J, Tasneem S, et al
Smartphone-Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial.
Headache. 2020 Nov 16. doi: 10.1111/head.14010.
PubMed Abstract available

LIPTON RB, Cohen JM, Bibeau K, Galic M, et al
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
Headache. 2020 Nov 11. doi: 10.1111/head.13997.
PubMed Abstract available

POLK AN, Protti TA, Smitherman TA
Allodynia and Disability in Migraine: The Mediating Role of Stress.
Headache. 2020 Nov 9. doi: 10.1111/head.14012.
PubMed Abstract available

DODICK DW, Gottschalk C, Cady R, Hirman J, et al
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
Headache. 2020 Nov 9. doi: 10.1111/head.14007.
PubMed Abstract available

PILATI L, Battaglia G, Di Stefano V, Di Marco S, et al
Migraine and Sport in a Physically Active Population of Students: Results of a Cross-Sectional Study.
Headache. 2020 Nov 7. doi: 10.1111/head.14015.
PubMed Abstract available

GILL K, Chia VM, Hernandez RK, Navetta M, et al
Rates of Vascular Events in Patients With Migraine: A MarketScan((R)) Database Retrospective Cohort Study.
Headache. 2020 Nov 3. doi: 10.1111/head.14001.
PubMed Abstract available

BUSE DC, McGinley JS, Lipton RB
Predicting the Future of Migraine Attack Prediction.
Headache. 2020;60:2125-2128.
PubMed

VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
The Sleep - Migraine Enigma: A Comment.
Headache. 2020;60:2610.
PubMed

FORD JH, Kurth T, Starling AJ, Ayer DW, et al
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
Headache. 2020;60:2304-2319.
PubMed Abstract available

October 2020

ANDERSON CC, Ray CA, Butler MR, Darken RS, et al
Effects of Procedural Discomfort and Expectation of Benefit on Therapy Continuation in Chronic Migraine Patients Treated With OnabotulinumtoxinA.
Headache. 2020 Oct 31. doi: 10.1111/head.14008.
PubMed Abstract available

BOLAY H, Ozge A, Uluduz D, Baykan B, et al
Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?
Headache. 2020 Oct 30. doi: 10.1111/head.13998.
PubMed Abstract available

KRYMCHANTOWSKI A, Jevoux C, Silva-Neto RP, Krymchantowski AG, et al
Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions.
Headache. 2020 Oct 27. doi: 10.1111/head.13999.
PubMed Abstract available

BLUMENFELD AM, Silberstein SD
Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice".
Headache. 2020 Oct 27. doi: 10.1111/head.13996.
PubMed

SMITHERMAN TA, Tietjen GE, Schuh K, Skljarevski V, et al
Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
Headache. 2020 Oct 16. doi: 10.1111/head.13970.
PubMed Abstract available

BUSE DC, Reed ML, Fanning KM, Bostic RC, et al
Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.
Headache. 2020 Oct 14. doi: 10.1111/head.13966.
PubMed Abstract available

TU S, Liew D, Ademi Z, Owen AJ, et al
The Health and Productivity Burden of Migraines in Australia.
Headache. 2020 Oct 7. doi: 10.1111/head.13969.
PubMed Abstract available

HOLSTEEN KK, Hittle M, Barad M, Nelson LM, et al
Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures.
Headache. 2020 Oct 6. doi: 10.1111/head.13960.
PubMed Abstract available

BEUTHIN J, Veronesi M, Grosberg B, Evans RW, et al
Gluten-Free Diet and Migraine.
Headache. 2020 Oct 6. doi: 10.1111/head.13993.
PubMed Abstract available

GHANSHANI S, Chen C, Lin B, Duan L, et al
Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
Headache. 2020 Oct 5. doi: 10.1111/head.13959.
PubMed Abstract available

TOMKINS E, Craven A, Ruttledge M
Migraine and Headache Care in the Republic of Ireland: History and a Vision for the Future Influenced by the COVID-19 Pandemic.
Headache. 2020 Oct 3. doi: 10.1111/head.13985.
PubMed Abstract available

September 2020

SWART ECS, Good CB, Henderson R, Manolis C, et al
Identifying Outcome Measures for Migraine Value-Based Contracting Using the Delphi Method.
Headache. 2020 Sep 30. doi: 10.1111/head.13978.
PubMed Abstract available

CHENG S, Jenkins B, Limberg N, Hutton E, et al
Erenumab in Chronic Migraine: An Australian Experience.
Headache. 2020 Sep 29. doi: 10.1111/head.13968.
PubMed Abstract available

HAMILTON KT, Halker Singh RB, Ailani J, Butterfield RJ, et al
Migraine Treatment in Pregnancy: An American Headache Society Survey.
Headache. 2020 Sep 29. doi: 10.1111/head.13974.
PubMed

FRIEDMAN BW, Irizarry E, Williams A, Solorzano C, et al
A Randomized, Double-Dummy, Emergency Department-Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine.
Headache. 2020 Sep 27. doi: 10.1111/head.13961.
PubMed Abstract available

QUINTAS M, Neto JL, Sequeiros J, Sousa A, et al
Going Deep into Synaptic Vesicle Machinery Genes and Migraine Susceptibility - A Case-Control Association Study.
Headache. 2020 Sep 26. doi: 10.1111/head.13957.
PubMed Abstract available

TOPTAN T, Aktan C, Basari A, Bolay H, et al
Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom.
Headache. 2020;60:1788-1792.
PubMed Abstract available

SAMPAIO ROCHA-FILHO PA, Voss L
Persistent Headache and Persistent Anosmia Associated With COVID-19.
Headache. 2020;60:1797-1799.
PubMed

PORTA-ETESSAM J, Matias-Guiu JA, Gonzalez-Garcia N, Gomez Iglesias P, et al
Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals.
Headache. 2020;60:1697-1704.
PubMed Abstract available

BOBKER SM, Robbins MS
COVID-19 and Headache: A Primer for Trainees.
Headache. 2020;60:1806-1811.
PubMed Abstract available

LIPTON RB, Seng EK, Chu MK, Reed ML, et al
The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
Headache. 2020;60:1683-1696.
PubMed Abstract available

July 2020

MINEN MT, Jaran J, Boyers T, Corner S, et al
Understanding What People With Migraine Consider to be Important Features of Migraine Tracking: An Analysis of the Utilization of Smartphone-Based Migraine Tracking With a Free-Text Feature.
Headache. 2020;60:1402-1414.
PubMed Abstract available

SUZUKI K, Fujita H, Hirata K
Parkinson's Disease and Headache: Is there a Relevant Relationship?
Headache. 2020;60:1440-1441.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.